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Letters to the Editorin addition to the SUVmax found on
PET–CT,2 the predictive values of the
solid tumor size found on HRCT for
pathologic high-grade malignancy
and prognosis in patients with clinical
stage IA lung adenocarcinoma are
greater than those of whole tumor
size, including solid and GGO compo-
nents. We strongly recommend that
solid tumor size be used to determine
the T descriptor in the TNM classifica-
tion of lung cancer and should be de-
fined as the true tumor size in cases of
lung adenocarcinoma with a GGO
component visualized on HRCT.
The suggestion regarding a tech-
nique in PET–CT scan for lung lesions
affected by physiologic motion is jus-
tified. The difference between the CT
volume and the gated PET volume is
significantly less than the difference
between the CT volume and the un-
gated PET volume.5 Respiratory gat-
ing has the potential to enhance
imaging of organs in motion, such as
lungs, and although some additional
time is needed for setup and acquisi-
tion, it can be incorporated practically
and efficiently into clinical routine.
Alternatively, breath-holding might
be used during diagnostic PET–CT if
true respiratory gating is not available.
Our belief, based on our data, is that
the optimal surgical strategy for
cT1N0M0 adenocarcinomas can be
chosen using the solid tumor size
found onHRCTand anSUVmax found
on 18F-fluorodeoxyglucose PET–CT.
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j.jtcvs.2012.12.080NEW STANDARD IN LUNG
CANCER STAGING? AWORD
OF WARNING
To the Editor:
We read with interest the recent ar-
ticle by Yendamuri and Demmy1 con-
cerning the field of our long-standing
scientific interest. We are glad that
they share our fascination with the
transcervical approach to the medias-
tinum; however, fascination with tech-
nique should not let us turn a blind eye
to other, perhaps more important,
aspects of surgery.
As the Yendamuri and Demmy1
stated, transcervical extended medias-
tinal lymphadenectomy (TEMLA) is
only used in a very few centers. We
therefore draw the attention of the sur-
gical community to some important
issues missed by the Yendamuri and
Demmy.1
Discussing complications ofTEMLA,
Yendamuri and Demmy1 only men-
tioned the recurrent laryngeal nerve
palsy in 2.3% of patients. This state-
ment may yield a false impression of
safety. In fact, the rate of complica-
tions is high: in the original article on
83 patients,2 it was 13.2% and apartof Thoracic and Cardiovascular Surgerfrom recurrent nerve palsy included
respiratory insufficiency, arrhythmia,
pneumothorax, and deterioration in
mental status. What is even more
important, general fitness of 21% of
patients deteriorated after TEMLA,
to the degree of making them medi-
cally unfit for operation, although all
were initially considered surgical
candidates.2
The next article, analyzing results
in 256 patients, showed a complication
rate of 11.3% with a mortality as high
as 1.2%. Again, more than 21% of the
176 node-negative patients became
unfit for surgery because of deteriora-
tion of their general condition.3
In an updated series of 587 patients
published 3 years later, the mortality
was 0.9%.4
Complications of TEMLA may be
severe. Apart from the recurrent nerve
palsy mentioned by Yendamuri and
Demmy,1 they include perforation of
themain bronchus, superior vena caval
laceration, left phrenic nerve palsy,
and injury to the innominate artery.
The least important drawback of the
TEMLA is its operative time, which
may be as long as 161 minutes.
The readers should be aware that
these results were achieved in a very
experienced center, by surgeons espe-
cially devoted to this technique. The
complication rate in less experienced
hands is likely to be even higher.
The first question to be answered is
whether it is acceptable to use a stag-
ing procedure that is associated with
mortality comparable to pulmonary
lobectomy. The second, equally im-
portant, question is whether it is ac-
ceptable to use a staging procedure
that makes 21% of patients unfit for
curative-intent surgery. The obvious
answer to both these questions is no.
A different consideration is the use
of transcervical lymph node dissection
as an element of curative-intent pul-
monary resection. If extended medias-
tinal lymphadenectomydoes influence
survival, this approach would be inter-
esting.Atpresent, there arenopublished
data in this regard. Also, data regardingy c Volume 145, Number 4 1149
Letters to the Editorthe long-term survival of patients
undergoing pulmonary resection after
TEMLA have never been published.
The transcervical approach to the
mediastinum is fascinating indeed.
Its applications warrant investigation
in well-designed clinical trials and, if
justified by these trials, implementa-
tion into routine practice. We should
not, however, allow our fascination
to blur our objectivity and clear vision
of all aspects of the matter. Safety of
our patients is certainly a priority.
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Weappreciate the interest in our arti-
cle demonstrated by Ku _zd _za1 and col-
leagues. In response, we would like to
draw their attention to several facts.
First, in our article we clearly stated
that transcervical extended mediastinal
lymphadenectomy(TEMLA)andvideo-
assisted mediastinal lymphadenec-
tomy (VAMLA) are more invasive
than mediastinoscopy or endobron-
chial ultrasonography and therefore
should only be considered in specific1150 The Journal of Thoracic andsituations. Such circumstances gener-
ally involve the suspicion of N2 or N3
involvement not detected by imaging,
particularly when the detection of
such disease would change surgical
options. Therefore Ku _zd _za1 and col-
leagues’ call for safety is echoed by
us as well.
Second, most TEMLA and
VAMLA reports are from a few select
centers. The safety of these proce-
dures should be replicated by many
other centers before the techniques
are accepted by the surgical commu-
nity at large. This point was made in
our article multiple times.
Third, several statistics are quoted
by Ku _zd _za1 and colleagues that point
out potential downsides of TEMLA.
For example, the overall high rate of
morbidity is quoted from their refer-
ences, but the highest proportion of
morbidity is a widened mediastinum,
which is of doubtful functional
significance.1,2 The 1.2% mortality
from TEMLA that they mentioned
also seems erroneous, as the reference
cited clearly states that the mortality
was not related to the procedure itself.
Ku_zd _za1 and colleagues also mention
isolated instances of injury to
mediastinal structures; however, this
is a well-known complication of medi-
astinal surgery in general, and such in-
stances have been reported with
mediastinoscopy as well.3 Of the vari-
ous complications noted in the commu-
nication of Ku _zd _za1 and colleagues,
perhaps the most concerning is the
statement that 21% of patients become
unfit for further surgerysolelyasa result
of TEMLA; however, this seems to be
their inference rather than a result de-
clared in the articles they referenced.
Contrary to this inference, the final cita-
tion included in their letter (a 2010anal-
ysis of 587 TEMLA patients) reported
a 6.8% complication rate, with 2.1%
major enough to limit subsequent thora-
cotomy, anda15% aggregateTEMLA-
negative nonthoracotomy rate. This
15% (not 21%) contains some patients
unfit for thoracotomy who underwent
surgical staging for better treatmentCardiovascular Surgery c April 2013planning (nonthoracotomy rates ap-
proach 10% in mediastinoscopy se-
ries). Intuitively, enhanced TEMLA
and VAMLA dissections should be
a bit more prone to complications than
mediastinoscopy when performed as
isolated procedures.Whenwe integrate
themwith video-assisted thoracoscopic
surgery or thoracotomy under the same
anesthetic, however, we just observe
a different surgical approach for the
same mediastinal lymph node dissec-
tion and do not expect substantial addi-
tional morbidity. Finally it is important
to note that TEMLA and VAMLA use
most of the safe exposure techniques
from well-validated procedures such
as mediastinoscopy and transcervical
thymectomy.
Therefore, although we agree that
TEMLA and VAMLA deserve further
study in multiple centers to assess
generalizability of safety and lymph
node yield, we do not see anything in
the current literature that raises safety
concerns to the extent interpreted by
Ku _zd _za1 and colleagues. If such data
exist, they ought to be published.
Certainly in our unpublished experi-
ence with more than 100 (mostly post-
induction) patients, we have not seen
any sign of prohibitive morbidity. It
is uncertain whether new surgical
approaches such as these will be
evaluated by adequately powered
randomized clinical trials. Until they
are, our surgical community will
have to judge their utility by thought-
fully interpreting retrospective
studies.
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